150 related articles for article (PubMed ID: 23497965)
1. Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma.
Wang P; Pei R; Lu Z; Rao X; Liu B
J Chin Med Assoc; 2013 Mar; 76(3):135-9. PubMed ID: 23497965
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
3. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
4. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
[TBL] [Abstract][Full Text] [Related]
5. [Aberrant methylation of hMLH1 gene promoter in papillary thyroid cancer and its clinical significance].
Lu XX; Ge MH; Ling ZQ; Hu SS; Xu J; Zheng CM; Tan Z; Chen C
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):833-6. PubMed ID: 24447481
[TBL] [Abstract][Full Text] [Related]
6. Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer.
Zhao H; Li J; Li X; Han C; Zhang Y; Zheng L; Guo M
Curr Protein Pept Sci; 2015; 16(4):316-21. PubMed ID: 25929866
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between methylation status of promoter and expression of XAF1 gene in papillary thyroid carcinoma].
Yin DT; Chen G; Li HQ; Zheng XY; Wang YF; Zhang Y; Jiang JH; Wang QD
Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(28):1967-70. PubMed ID: 22944270
[TBL] [Abstract][Full Text] [Related]
9. DNA hypermethylation status of multiple genes in papillary thyroid carcinomas.
Ishida E; Nakamura M; Shimada K; Higuchi T; Takatsu K; Yane K; Konishi N
Pathobiology; 2007; 74(6):344-52. PubMed ID: 18087199
[TBL] [Abstract][Full Text] [Related]
10. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.
Beltrami CM; Dos Reis MB; Barros-Filho MC; Marchi FA; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
Clin Epigenetics; 2017; 9():45. PubMed ID: 28469731
[TBL] [Abstract][Full Text] [Related]
11. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
12. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
13. Correlation of DNA methylation and lymph node metastasis in papillary thyroid carcinoma.
Zhao F; Zhu S; Fang J; Dong H; Zhu C
Head Neck; 2023 Jul; 45(7):1654-1662. PubMed ID: 37097909
[TBL] [Abstract][Full Text] [Related]
14. Preoperative ultrasonographic features of papillary thyroid carcinoma predict biological behavior.
Nam SY; Shin JH; Han BK; Ko EY; Ko ES; Hahn SY; Chung JH
J Clin Endocrinol Metab; 2013 Apr; 98(4):1476-82. PubMed ID: 23463652
[TBL] [Abstract][Full Text] [Related]
15. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma.
Schagdarsurengin U; Gimm O; Dralle H; Hoang-Vu C; Dammann R
Thyroid; 2006 Jul; 16(7):633-42. PubMed ID: 16889486
[TBL] [Abstract][Full Text] [Related]
16. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
17. Methylation of CpG islands of p16 associated with progression of primary gastric carcinomas.
Luo D; Zhang B; Lv L; Xiang S; Liu Y; Ji J; Deng D
Lab Invest; 2006 Jun; 86(6):591-8. PubMed ID: 16534497
[TBL] [Abstract][Full Text] [Related]
18. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
19. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
Sassa M; Hayashi Y; Watanabe R; Kikumori T; Imai T; Kurebayashi J; Kiuchi T; Murata Y
Thyroid; 2011 May; 21(5):511-7. PubMed ID: 21449767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
